Skip to main content
SunBio, Inc. logo

SunBio, Inc. — Investor Relations & Filings

Ticker · 067370 ISIN · KR7067370007 KO Manufacturing
Filings indexed 213 across all filing types
Latest filing 2025-10-01 Regulatory Filings
Country KR South Korea
Listing KO 067370

About SunBio, Inc.

http://www.sunbio.com/

SunBio, Inc. is a biotechnology company that develops biosimilars, biopharmaceuticals, and medical devices. The company's core activities are based on its proprietary PEGylation technology, a process that modifies molecules to enhance their therapeutic properties. SunBio's product portfolio includes PEG reagents for research and drug delivery, as well as biopharmaceutical candidates. Key development projects include MucoPEG™, a muco-adhesive hydrogel, and SBX, an artificial blood substitute. The company positions itself as a specialist in PEGylation, creating advanced therapeutic products for a global market.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2025-10-01 Korean
신탁계약해지결과보고서
Regulatory Filings
2025-09-26 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-annual Report) for SunBio Co., Ltd., covering the period from January 1, 2025, to June 30, 2025. It contains detailed company information, business operations, financial status, and management discussions, which are characteristic of an interim/quarterly financial report. It is not an announcement of a report, but the report itself. H1 2025
2025-08-14 Korean
자기주식취득결과보고서
Transaction in Own Shares Classification · 1% confidence The document is a '자기주식취득결과보고서' (Report on the Results of Treasury Stock Acquisition) filed with the Financial Supervisory Service (금융감독원). This document details the specific dates, quantities, and prices of shares repurchased by SunBio Co., Ltd. within a specified period. According to the provided filing definitions, reports regarding a company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2025-06-26 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for SunBio Co., Ltd. for the period ending March 31, 2025. It contains detailed financial information, business operations, management discussion, and capital structure, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
전환가액의조정 (제4회차)
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory announcement regarding the adjustment of the conversion price for convertible bonds (CB) due to a decline in the company's stock price. This type of filing, which details changes to capital structure instruments like convertible bonds, falls under the category of capital and financing updates.
2025-04-07 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.